Valuation dashboard for Metagenomi, Inc. Common Stock (MGX) with P/E N/A, P/B 0.38, EV/EBITDA -0.48 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases.
Analysis Summary
Trailing-twelve-month margins: gross margin 74.3%, operating margin -7.4%, net margin -6.9%.
At the current price of $1.15, MGX has negative trailing earnings (P/E not meaningful) and an ROE of -63.65%. Market capitalisation stands at $43M.
Balance sheet quality for MGX: current ratio of 7.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.38 |
| EV / EBITDA | -0.48 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MGX | Metagenomi, Inc. Common Stock | $43M | 0.38 | -63.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.15 |
| Market Cap | $43M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -63.65% |
| Return on Invested Capital | -65.88% |
| Return on Assets | -53.81% |
| Gross Margin | 74.29% |
| Operating Margin | -741.58% |
| Net Margin | -689.20% |
Related companies: ADVM · ALXO · ARTV · ATYR · CNTB · DTIL · IFRX
Explore sector: Healthcare · Biotechnology
More sections of MGX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks